Macrobiome Therapeutics
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Inflammation
Macrobiome Therapeutics (MBT) is pioneering a new class of therapeutics for inflammatory bowel disease (IBD) by harnessing millions of years of co-evolution between humans and hookworms, translating the immune-regulating mechanisms of hookworm proteins into safe, targeted therapies. Unlike conventional biologics that broadly suppress immunity, MBT’s approach restores immune balance by acting upstream of key inflammatory pathways, offering the potential for greater efficacy and improved safety. MBT’s proprietary discovery platform—built on the world’s largest library of hookworm-derived proteins—has delivered lead candidates MBT-001 and MBT-002, which demonstrate strong preclinical efficacy and human translational potential. MBT is positioned to deliver first-in-class, immune-rebalancing therapies through strategic partnerships and clinical development and is seeking $25M Series A investment to fund the next phase of development.
Company HQ City:
Caravonica
Company HQ State:
Queensland
Company HQ Country:
Australia
Year Founded:
2020
Lead Product in Development:
MBT-001 in inflammatory bowel disease
CEO
Keats Nelms
Development Phase of Lead Product
Pre-Clinical
When you expect your next catalyst update?
August 2026
What is your next catalyst (value inflection) update?
Nomination of development lead
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}